Table 3.

Analysis of toxicities and side effects stratified by days of single-cycle SFI dosing.

Subgroups	Number of studies	SFI+PBC n/N	PBC n/N	Heterogeneity	PooledRRs(95%CI)	Z	P
Hemoglobinia
8-14d	11	94/421	163/414	P=0.76, I2 = 0%	0.56(0.46–0.69)	5.52	<0.00001
15-28d	6	51/221	88/220	P=0.43, I2 = 0%	0.58(0.43–0.77)	3.70	0.0002
Total	17	145/642	251/634	P=0.78, I2 = 0%	0.57(0.48–0.67)	6.63	<0.00001
Leukopenia
0-7d	2	33/66	50/66	P=0.32, I2 = 0%	0.69(0.54–0.89)	2.91	0.004
8-14d	16	267/643	419/637	P<0.00001, I2 = 85%	0.62(0.49–0.78)	4.13	<0.0001
15-28d	11	160/462	275/461	P=0.15, I2 = 31%	0.59(0.50–0.71)	5.82	<0.00001
UN	1	15/40	25/40	Not applicable	0.60(0.38–0.96)	2.15	0.03
Total	30	475/1211	769/1204	P<0.00001, I2 = 77%	0.61(0.53–0.71)	6.49	<0.00001
Thrombocytopenia
0-7d	2	13/66	30/66	P=0.56, I2 = 0%	0.43(0.25–0.75)	3.01	0.003
8-14d	14	170/571	250/563	P=0.23, I2 = 21%	0.67(0.58–0.78)	5.27	<0.00001
15-28d	10	101/385	167/383	P=0.13, I2 = 34%	0.60(0.49–0.74)	4.89	<0.00001
UN	1	11/40	22/40	Not applicable	0.50(0.28–0.89)	2.36	0.02
Total	27	295/1062	469/1052	P=0.12, I2 = 25%	0.62(0.55–0.70)	8.05	<0.00001
Myelosuppression
Total	3	35/125	67/128	P=0.53, I2 = 0%	0.55(0.41–0.73)	4.01	<0.0001
Nausea and vomiting
8-14d	12	195/494	307/502	P<0.0001, I2 = 71%	0.65(0.51–0.84)	3.28	0.001
15-28d	6	64/225	113/224	P=0.34, I2 = 11%	0.59(0.46–0.76)	4.01	<0.0001
Total	18	259/719	420/726	P=0.0002, I2 = 63%	0.63(0.52–0.77)	4.63	<0.00001
Diarrhea
Total	5	46/229	96/234	P=0.11, I2 = 47%	0.48(0.37–0.64)	5.09	<0.00001
Gastrointestinal Reaction
0-7d	2	40/66	52/66	P=0.02, I2 = 82%	0.71(0.36–1.43)	0.95	0.34
8-14d	3	38/120	65/110	P=0.12, I2 = 53%	0.56(0.36–0.88)	2.55	0.01
15-28d	5	82/193	129/192	P<0.0001, I2 = 85%	0.63(0.40–0.99)	2.02	0.04
UN	1	14/40	25/40	Not applicable	0.56(0.34–0.91)	2.34	0.02
Total	11	174/419	271/408	P<0.00001, I2 = 78%	0.63(0.49–0.80)	3.67	0.0002

n,number of cases with adverse reactions; N,total number of cases included in this study; UN,Unclear.